Company research / GYRE
Gyre Therapeutics, Inc. (GYRE)
- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
For the year ended 2025-12-31, Gyre Therapeutics, Inc. reported revenue of $116.59M. Revenue grew 10.2% from the prior annual period.
Key ratios (year ended 2025-12-31)
9.9%
Operating margin
8.5%
Net margin
9.3%
Return on year-end equity
10.2%
Revenue growth (YoY)
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.